OBJECTIVE: To compare the efficacy of leuprolide and continuous oral contraceptives in the treatment of endometriosis-associated pain. DESIGN: Prospective, randomized, double-blind controlled trial. SETTING:Academic medical centers in Rochester, New York, and Boston, Massachusetts. PATIENT(S): Forty-seven women with endometriosis-associated pelvic pain. INTERVENTION(S): Forty-eight weeks of either depot leuprolide, 11.25 mg IM every 12 weeks with hormonal add-back using norethindrone acetate 5 mg orally, daily; or a generic monophasic oral contraceptive (1 mg norethindrone + 35 mg ethinyl estradiol) given daily. MAIN OUTCOME MEASURE(S): Biberoglu and Behrman (B&B) pain scores, numerical rating scores (NRS), Beck Depression Inventory (BDI), and Index of Sexual Satisfaction (ISS). RESULT(S): Based on enrollment of 47 women randomized tocontinuous oral contraceptives and to leuprolide, there were statistically significant declines in B&B, NRS, and BDI scores from baseline in both groups. There were no significant differences, however, in the extent of reduction in these measures between the groups. CONCLUSION(S): Leuprolide and continuous oral contraceptives appear to be equally effective in the treatment of endometriosis-associated pelvic pain.
RCT Entities:
OBJECTIVE: To compare the efficacy of leuprolide and continuous oral contraceptives in the treatment of endometriosis-associated pain. DESIGN: Prospective, randomized, double-blind controlled trial. SETTING: Academic medical centers in Rochester, New York, and Boston, Massachusetts. PATIENT(S): Forty-seven women with endometriosis-associated pelvic pain. INTERVENTION(S): Forty-eight weeks of either depot leuprolide, 11.25 mg IM every 12 weeks with hormonal add-back using norethindrone acetate 5 mg orally, daily; or a generic monophasic oral contraceptive (1 mg norethindrone + 35 mg ethinyl estradiol) given daily. MAIN OUTCOME MEASURE(S): Biberoglu and Behrman (B&B) pain scores, numerical rating scores (NRS), Beck Depression Inventory (BDI), and Index of Sexual Satisfaction (ISS). RESULT(S): Based on enrollment of 47 women randomized to continuous oral contraceptives and to leuprolide, there were statistically significant declines in B&B, NRS, and BDI scores from baseline in both groups. There were no significant differences, however, in the extent of reduction in these measures between the groups. CONCLUSION(S): Leuprolide and continuous oral contraceptives appear to be equally effective in the treatment of endometriosis-associated pelvic pain.
Authors: F Parazzini; L Fedele; M Busacca; L Falsetti; S Pellegrini; P L Venturini; M Stella Journal: Am J Obstet Gynecol Date: 1994-11 Impact factor: 8.661
Authors: U Ulrich; O Buchweitz; R Greb; J Keckstein; I von Leffern; P Oppelt; S P Renner; M Sillem; W Stummvoll; R-L De Wilde; K-W Schweppe Journal: Geburtshilfe Frauenheilkd Date: 2014-12 Impact factor: 2.915
Authors: Jenny Sadler Gallagher; Henry A Feldman; Natalie A Stokes; Marc R Laufer; Mark D Hornstein; Catherine M Gordon; Amy D DiVasta Journal: J Pediatr Adolesc Gynecol Date: 2016-02-27 Impact factor: 1.814
Authors: U Ulrich; O Buchweitz; R Greb; J Keckstein; I von Leffern; P Oppelt; S P Renner; M Sillem; W Stummvoll; K-W Schweppe Journal: Geburtshilfe Frauenheilkd Date: 2013-09 Impact factor: 2.915
Authors: Fadi Abushahin; Kara N Goldman; Elizabeth Barbieri; Magdy Milad; Alfred Rademaker; Serdar E Bulun Journal: Fertil Steril Date: 2011-08-24 Impact factor: 7.329
Authors: Samir N Babayev; Chan Woo Park; Patrick W Keller; Bruce R Carr; Ruth A Word; Orhan Bukulmez Journal: Reprod Sci Date: 2017-02-12 Impact factor: 3.060